Previous 10 | Next 10 |
2024-04-03 12:27:33 ET More on Arbutus Biopharma Arbutus Biopharma Corporation (ABUS) Q4 2023 Earnings Call Transcript Arbutus Biopharma GAAP EPS of -$0.44 beats by $0.01, revenue of $18.1M misses by $3.04M Arbutus Biopharma gains after Markman hearing on Thursday in...
CAMBRIDGE, MA / ACCESSWIRE / April 3, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that interim data for a first-in-human, phase 1/2, open-label, dose optimization study and extension study, evaluating the safety and efficacy of mRNA-3927, an investigational mRNA therapy for propionic acid...
2024-04-01 15:52:03 ET For many, Moderna (NASDAQ: MRNA) stock is yesterday's news. The stock earned a great deal of attention during the coronavirus pandemic, as it was one of the early developers of a vaccine to fight off the global health scourge. Since then, it's been a bit of an...
2024-04-01 13:52:08 ET More on Carisma Therapeutics Carisma Therapeutics: New Frontiers In Cell Therapy, But Too Early To Buy In Seeking Alpha’s Quant Rating on Carisma Therapeutics Historical earnings data for Carisma Therapeutics Financial informatio...
2024-04-01 11:21:19 ET More on S&P 500 Index: China PMI Is Better Than Expected But The Greenback Still Rises Above CNY7.23 The March Labor Report Preview: The Cracks Are Deepening S&P 500 Closes Its Best Quarter Since 2019 At Record High Top 20 S&...
2024-04-01 10:15:00 ET No pair of companies dominated the COVID-19 vaccine market quite like Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) . Both saw their revenue and earnings skyrocket, along with their share prices, as governments rushed to buy millions of doses of their ...
2024-04-01 05:05:00 ET A few years ago, both Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) were flying high: from an earnings and share performance perspective. They each sold a leading coronavirus vaccine -- and Pfizer sold a COVID treatment too -- and these products genera...
2024-03-28 09:06:17 ET “Biotech industry has found its footing again”, says Karen Andersen – a Morningstar strategist. Here are the top U.S. based stocks within this space that are particularly worth owning for 2024. Vertex Pharmaceuticals Inc (NASDAQ: VRTX) ...
2024-03-28 09:00:06 ET Michael Yee from Jefferies issued a price target of $125.00 for MRNA on 2024-03-28 07:49:00. The adjusted price target was set to $125.00. At the time of the announcement, MRNA was trading at $110.59. The overall price target consensus is at $173.6...
2024-03-28 07:15:01 ET Goldman Sachs analyst issues BUY recommendation for MRNA on March 28, 2024 05:33AM ET. The previous analyst recommendation was Buy. MRNA was trading at $110.59 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update. A live webcast of the c...
CAMBRIDGE, MA AND OSAKA, JAPAN / ACCESSWIRE / July 8, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Mitsubishi Tanabe Pharma Corporation today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including ...
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical...